Endothelial markers and HIV infection in the era of highly active antiretroviral treatment

Thrombosis Research

Volumn 110, Issue 2-3, 2003, Pages 93-98

  De Larrañaga, Gabriela F ^a   Bocassi, Andrea R ^a   Puga, Liliana M ^a   Alonso, Beatriz S ^a   Benetucci, Jorge A ^a  

^a Infectious Diseases Hospital   (Argentina)

Author keywords

Endothelium; HIV; Lipodystrophy; Thrombomodulin; Vascular cell adhesion molecule 1; Von Willebrand factor

Indexed keywords

ANTIVIRUS AGENT; APOLIPOPROTEIN; BIOLOGICAL MARKER; FAT; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THROMBOMODULIN; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ADULT; ARM; ARTICLE; BODY FAT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; ENDOTHELIUM INJURY; FEMALE; HEALTH STATUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LEG; LIPID ANALYSIS; LIPOATROPHY; LIPODYSTROPHY; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 4243917624     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(03)00291-3     Document Type: Article

References (31)

1. Cines D.B., Pollak E.S., Buck C.A., Loscalzo J., Zimmerman G.A., McEver R.P.et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood. 91:1998;3527-3561.
2. Pober J.S. Cytokine-mediated activation of vascular endothelium. Am. J. Pathol. 133:1988;426-433.
3. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 362:1993;801-808.
4. Blann A.D., Taberner D.A. A reliable marker of endothelial cell dysfunction: does it exist? Br. J. Haematol. 90:1995;244-248.
5. Blann A.D., Maxwell S.R.J., Burrows G., Miller J.P. Antioxidants, von Willebrand factor and endothelial cell injury in hypercholesterolaemia and vascular disease. Atherosclerosis. 116:1995;191-198.
6. Blann A., Seigneur M. Soluble markers of endothelial cell function. Clin. Hemorheol. 17:1997;3-11.
7. Lip G.Y.H., Blann A. von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc. Res. 34:1997;255-265.
8. Blann A.D., Seigneur M., Steiner M., Miller I.P., McCollum C.N. Circulating ICAM-1 and VCAM-1 in peripheral artery disease and hypercholesterolaemia: relationship to the location of atherosclerotic disease, smoking and in the prediction of adverse events. Thromb. Haemost. 79:1998;1080-1085.
9. Blankenberg S., Rupprecht H.J., Bickel C., Peetz D., Hafner G., Tiret L.et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation. 104:2001;1336-1342.
10. Friedman H.M. Infection of endothelial cells by common human viruses. Rev. Infect. Dis. 2:1989;S700-S704.
11. Lafeuillade A., Alessi M.C., Poizot-Martin I., Boyer-Neumann C., Zandotti C., Quilichini R.et al. Endothelial cell dysfunction in HIV infection. JAIDS. 5:1992;127-131.
12. Seigneur M., Constans J., Blann A., Renard M., Pellegrin J.L., Amiral J.et al. Soluble adhesion molecules and endothelial cell damage in HIV infected patients. Thromb. Haemost. 77:1997;646-649.
13. Schved J.F., Gris J.C., Arnaud A., Martinez P., Sanchez N., Wautier J.L.et al. Von Willebrand factor antigen, tissue-type plasminogen activator antigen, and risk of death in human immunodeficiency virus 1-related clinical disease: independent prognostic relevance of tissue-type plasminogen activator. J. Lab. Clin. Med. 120:1992;411-419.
14. de Larrañaga G.F., Petroni A., Deluchi G., Alonso B.S., Benetucci J.A. Viral load and diseases progression as responsible for endothelial activation and/or injury in HIV-1 infected patients. Blood Coagul. Fibrinolysis. 14:2002;15-18.
15. Safrin S., Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS. 13:1999;2493-2505.
16. Grinspoon S. Insulin resistance in the HIV-lipodystrophy syndrome. Trends Endocrinol. Metab. 9:2001;413-419.
17. Carr A., Samaras K., Thorisdottir A., Kaufmann G.R., Chisholm D.J., Cooper D.A. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 353:1999;2093-2099.
18. Van der Kooy K., Seidell J.C. Techniques for measurement of visceral fat: a practical guide. Int. J. Obes. Relat. Metab. Disord. 17:1993;187-196.
19. Centers for Diseases Control and Prevention 1993 revised classification system for HIV infection and expanded surveillance of definition for AIDS among adolescents and adults. MMWR. 41(RR-17):1992;1-19.
20. Staal F.J., Ela S.W., Roederer M., Anderson M.T., Herzenberg L.A., Herzenberg L.A. Glutathione deficiency and human immunodeficiency virus infection. Lancet. 339:1992;909-912.
21. Constans J., Seigneur M., Blann A.D., Renard M., Resplandy F., Amiral J.et al. Effect of the antioxidants selenium and beta-carotene on HIV-related endothelium dysfunction. Thromb. Haemost. 80:1998;1015-1017.
22. Currier J., Carpenter C., Daar E., Kotler D., Wanke C. Identifying and managing morphologic complications of HIV and HAART. AIDS Read. 12:2002;114-125.
23. Mallal S.A., John M., Moore C.B., James I.R., McKinnon E.J. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS. 14:2000;1309-1316.
24. Tsekes G., Chrysos G., Douskas G., Paraskeva D., Mangafas N., Giannakopoulos D.et al. Body composition changes in protease inhibitor-naïve HIV-infected patients treated with two nucleoside reverse transcriptase inhibitors. HIV Med. 3:2002;85-90.
25. Aukrust P., Bjørnsen S., Lunden B., Otterdal K., Ng E.C., Ameln W.et al. Persistently elevated levels of von Willebrand factor antigen in HIV infection. Thromb. Haemost. 84:2000;183-187.
26. Hober D., Haque A., Wattre P., Beaucaire G., Mouton Y., Capron A. Production of tumor necrosis factor-alpha (TNFα) and interleukin-1 (IL-1) in patients with AIDS. Enhanced levels of TNFα is related to a higher cytotoxic activity. Clin. Exp. Immunol. 78:1989;329-333.
27. Poli G., Bressler P., Kinter A., Duh E., Timmer W.C., Rabson A.et al. Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor α by transcriptional and post-transcriptional mechanisms. J. Exp. Med. 172:1990;151-158.
28. Wolf K., Tsakiris D.A., Weber R., Erb P., Battegay M. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type-1. JID. 185:2002;456-462.
29. Périard D., Telenti A., Sudre P., Cheseaux J.J., Halfon P., Reymond M.J.et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation. 100:1999;700-705.
30. Mercie P., Tchamgoue S., Thiebaut R., Viallard J., Faure I.I., Dancourt V.V.et al. Atherogen lipid profile in HIV-1-infected patients with lipodystrophy syndrome. Eur. J. Intern. Med. 11:2000;257-263.
31. Koppel K., Bratt G., Eriksson M., Sandstrom E. Serum lipid levels associated with increased risk for cardiovascular disease is associated with highly active antiretroviral therapy (HAART) in HIV-1 infection. Int. J. STD AIDS. 11:2000;451-455.